These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 27940287

  • 1. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
    Watz H, Mailänder C, May C, Baier M, Kirsten AM.
    Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
    [Abstract] [Full Text] [Related]

  • 2. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M.
    Int J Chron Obstruct Pulmon Dis; 2016 Feb; 11():1425-34. PubMed ID: 27418815
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M.
    Eur J Pharmacol; 2015 Aug 15; 761():383-90. PubMed ID: 25952728
    [Abstract] [Full Text] [Related]

  • 4. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D.
    Lancet; 2017 May 13; 389(10082):1919-1929. PubMed ID: 28385353
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
    Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, Jung JY, Kim S, Hwang YI, Jung KS.
    Trials; 2017 Feb 22; 18(1):80. PubMed ID: 28228162
    [Abstract] [Full Text] [Related]

  • 6. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
    Santus P, Radovanovic D, Di Marco F, Raccanelli R, Valenti V, Centanni S.
    Pulm Pharmacol Ther; 2015 Dec 22; 35():42-9. PubMed ID: 26549785
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
    Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D.
    Lancet Respir Med; 2013 May 22; 1(3):199-209. PubMed ID: 24429126
    [Abstract] [Full Text] [Related]

  • 9. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T.
    Lancet Respir Med; 2018 May 22; 6(5):368-378. PubMed ID: 29477448
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study.
    Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E.
    Respir Med; 2017 Nov 22; 132():251-260. PubMed ID: 28919143
    [Abstract] [Full Text] [Related]

  • 11. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P, Hagedorn-Peinz I.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 22; 13():69-77. PubMed ID: 29317812
    [Abstract] [Full Text] [Related]

  • 12. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B, Dhembare P, Jantikar A, Mahadik P, Gokhale P, Gogtay JA, Salvi SS.
    Respir Med; 2007 Dec 22; 101(12):2464-71. PubMed ID: 17719763
    [Abstract] [Full Text] [Related]

  • 13. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
    Singh D, Scuri M, Collarini S, Vezzoli S, Mariotti F, Muraro A, Acerbi D.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 22; 12():2001-2014. PubMed ID: 28744115
    [Abstract] [Full Text] [Related]

  • 14. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H, Mailänder C, Baier M, Kirsten A.
    BMC Pulm Med; 2016 Jun 14; 16(1):95. PubMed ID: 27301417
    [Abstract] [Full Text] [Related]

  • 15. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D.
    Respir Med; 2014 Apr 14; 108(4):584-92. PubMed ID: 24534204
    [Abstract] [Full Text] [Related]

  • 16. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, Dahl R.
    Respir Res; 2015 Sep 15; 16(1):107. PubMed ID: 26369563
    [Abstract] [Full Text] [Related]

  • 17. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
    De Backer W, De Backer J, Vos W, Verlinden I, Van Holsbeke C, Clukers J, Hajian B, Siddiqui S, Jenkins M, Reisner C, Martin UJ.
    Int J Chron Obstruct Pulmon Dis; 2018 Sep 15; 13():2673-2684. PubMed ID: 30214185
    [Abstract] [Full Text] [Related]

  • 18. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
    Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.
    Respir Res; 2017 Jan 11; 18(1):13. PubMed ID: 28077140
    [Abstract] [Full Text] [Related]

  • 19. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z, TRIDENT study investigators.
    Respir Med; 2016 May 11; 114():84-90. PubMed ID: 27109816
    [Abstract] [Full Text] [Related]

  • 20. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial.
    Beaulieu J, Jensen D, O'Donnell DE, Brouillard C, Tracey L, Vincent S, Nadreau É, Bernard E, Bernard S, Maltais F.
    Ther Adv Respir Dis; 2020 May 11; 14():1753466620939507. PubMed ID: 32663102
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.